Category: Uncategorized

HONG KONG, Jan 6 (Bernama-BUSINESS WIRE) — Hong Kong’s iconic Victoria Harbour lit up exceptionally bright as the city rings in 2022, taking its thriving art scene right to the global centre stage.

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20211231005124/en/

At 11:59pm on 31 December 2021, the 65.8-metre-tall LED facade of M+, Asia’s first global museum of contemporary visual culture in the West Kowloon Cultural District, was transformed into a countdown clock, which travelled across the rich cityscape of Hong Kong.
 Once the clock struck midnight, a special edition of the multimedia show A Symphony of Lights cast a dazzling array of visual effects across Hong Kong’s famous skyline complemented by rooftop pyrotechnics and lighting effects launched at various elevations, along with New Year’s greetings in 15 different languages on the M+ Facade, sending sincere blessings to the rest of the world.

The dazzling light art extravaganza across the harbour was synchronised with energetic, jubilant music performed by the Hong Kong Philharmonic Orchestra, the city’s flagship orchestra, in an outdoor concert in the West Kowloon Cultural District.

Information of Video and Image Download

• The video footage and photos of Hong Kong New Year Countdown Celebrations can be downloaded from 1 January 2022, 03:00 Hong Kong Time (31 December 2021 GMT 19:00). Media interested in broadcasting the event may download the material from the link below.
  
  Download link: https://assetlibrary.hktb.com/assetbank-hktb/action/browseItems?categoryId=728&categoryTypeId=2&cachedCriteria=1

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20211231005124/en/

Contact

Mr Cameron Tong
Tel: (852) 2807 6367
Email: cameron.tong@hktb.com

Ms Vivian Li
Tel: (852) 2807 6206
Email: vivian.li@hktb.com

Source : Hong Kong Tourism Board

http://mrem.bernama.com/viewsm.php?idm=42080

KUALA LUMPUR, Jan 4 (Bernama) — Celltrion Group has announced results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529).

The Phase I clinical trial is a randomised, double-blind and placebo-controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.

“The positive results demonstrate the potential of our cocktail therapy to retain neutralising ability against the Omicron variant,” said Head of Medical and Marketing Division at Celltrion Healthcare, Dr HoUng Kim, Ph.D.

“We are confident that our antibody platform including Regkirona and CT-P63 will provide significant benefit for patients with COVID-19.”

According to a statement, the study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug-related adverse events (AEs).

In an experiment conducted in partnership with the National Institutes of Health (NIH), CT-P63 showed strong neutralising activity against the Omicron variant based on structural analysis by X- ray crystallography and neutralisation data from pseudo-virus testing.

Celltrion anticipates results of the SARS-CoV-2 Omicron variant assays and animal model studies by the end of the first quarter this year.

In order to elicit potent neutralising antibody response against the new emerging variants, Celltrion previously identified 38 potent neutralising antibodies against SARS-CoV-2 in which antibody candidate No. 32 (CT-P63) produced high neutralisation titres against new emerging strains.

More details at https://www.celltrionhealthcare.com/en-us.

— BERNAMA

KUALA LUMPUR, Dec 23 (Bernama) — Some poets, who have participated in the 5th Chengdu International Poetry Week recently, have had a field trip to Chengdu Research Base of Giant Panda Breeding.

Led by the staff of the research base, the participating poets took photos all the way to learn the name, age and personality of each giant panda.

Participating poets have found it very interesting that different giant pandas have different living habits and personalities, although they belong to the same species.

As a staff of a large-scale e-commerce company, Wang Erdong has written a series of poems with the ‘courier’ as the leading character. By observing this new profession that emerges in such a modern industrial society, he has expressed his thoughts on the new things brought about by modern industrial production.

That was Wang Erdong’s first time participating in the International Poetry Week, and it was also his first time visiting the research base.

Passing through the lush and verdant bamboo forest in the research base, the participating poets have also fully felt the ecological beauty of Chengdu. This is also an aspect of life in Chengdu, presenting the local unique beauty and poetry.

— BERNAMA

PUTRAJAYA, Dec 20 (Bernama) — As the year draws to a close, Tourism Malaysia via the Shopping Malaysia Secretariat has organised the Miss SHOPhia Virtual Hunt 2021 in an effort to promote shopping activities in Malaysia through the country’s digital shopping icon, Miss SHOPhia.

Befitting the current situation as the world adopts the “new normal” for the tourism industry, the Miss SHOPhia Virtual Hunt campaign took place on 18 December 2021 through the Zoom platform, with a total of 111 participants from within and outside the country (ASEAN). Each group consisted of four participants, including members of the public, local media, and representatives from ASEAN countries including public and media.

Participants were virtually brought in to solve mystery riddles using the notion of street shopping, cuisine, and the most recent tourist attractions in Langkawi, Kuala Lumpur, Pulau Pinang, Kuching, and Kota Kinabalu. Participants stood a chance to win prizes worth up to RM39,000, subject to the terms and conditions.

Officiated by YBhg. Dato’ Haji Zainuddin Abdul Wahab, the Director General of Tourism Malaysia, the virtual hunt aimed to provide an escape for those who have been missing to visit and explore Malaysia. “The Covid-19 pandemic has forced us to rethink and postpone our holiday trips but as the saying goes “absence makes the heart grow fonder”, I believe it has made us yearn and ignite our dreams to travel even more,” said Dato’ Haji Zainuddin.

The event was concluded by Mr Iskandar Mirza Mohd Yusof, Deputy Director General (Planning) of Tourism Malaysia. “Through this event, the participants are able to get to know some of the new tourist attractions and food diversity in Malaysia through virtual lenses from the comfort of their homes. With the reopening of borders especially to Langkawi on 15th November 2021, we hope that by experiencing this virtual event all of you will be eager to plan your holiday to Malaysia,” said Mr Iskandar Mirza.

To get updates from Miss SHOPhia, visit https://www.instagram.com/miss_shophia/.

About Tourism Malaysia

Malaysia Tourism Promotion Board, also known as Tourism Malaysia, is an agency under the Ministry of Tourism, Arts & Culture Malaysia. It focuses on the specific task of promoting Malaysia as a preferred tourism destination. Since its inception, it has emerged as a major player in the international tourism scene. In 2019, Malaysia registered 26.1 million tourist arrivals and RM86.14 billion tourist receipts, placing it among the major tourism destinations of the world.

SOURCE: Tourism Malaysia

http://mrem.bernama.com/viewsm.php?idm=42005

Milan, Dec 21 (Bernama-GLOBE NEWSWIRE) —AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.

The annual award honors companies fostering economic development and growth between Italy and the United States. Luca Alberici, AGC Biologics General Manager and Site Head of the Milan facility, received the award on behalf of the company during the XV Transatlantic Award Gala Dinner, held on December 2 at Studio 90 East End Studios in Milan.

The additional guests of honor at the award ceremony included Mariangela Zappia (AmCham Italy Honorary President and Ambassador of Italy to the United States of America), Thomas D. Smitham (Chargé d’Affaires and interim and U.S. Embassy to Italy), On. Giancarlo Giorgetti (Italian Minister of Economic Development) and On. Lorenzo Guerini (Italian Minister of Defense).  AGC Biologics was honored alongside other notable companies such as Apple, Coca-Cola, Diasorin and KKR.

 “I am happy and honored to receive this award on behalf of AGC Biologics. This is an important award that showcases the investments our company has made in our Milan site, as well as the growing biopharmaceutical industry in our region,” said AGC Biologics Milan General Manager and Site Head, Luca Alberici. “Our Center of Excellence, one of the best in world and our team of scientists and employees, who work hard every day with responsibility and professionalism, played a crucial role in the successes we’ve achieved over the last two years.”

AGC Biologics acquired the Milan facility when it purchased Molecular Medicine S.p.A. (“MolMed”) in 2020. Since that transaction, AGC Biologics has focused on supporting and developing the teams working at the site, and investing in expanding the site’s services, capabilities and production capacities. These commitments in the Milan facility have helped AGC Biologics become one of the most complete and active biotech CDMOs in the global healthcare market.

The AGC Biologics Milan site was the first GMP facility approved in Europe for ex-vivo gene therapy manufacturing and has industry-unique commercial manufacturing experience, having previously brought three cell & gene therapy products to the market.

To complement the Center of Excellence in Milan, the company recently opened a new facility in Longmont, CO., USA, which will help AGC Biologics expand its global capacity for cell and gene therapy development and manufacturing. Through these two key sites, AGC Biologics can now offer more capacity and services to pharmaceutical companies worldwide developing new life-changing cell and gene therapy products.

About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

Nick McDonald
AGC Biologics
(425) 419-3555
nmcdonald@agc.com 

SOURCE : AGC Biologics